ESG: Creating Greener Clinical Trials

Life Sciences, Clinical Trials,
  • Wednesday, April 26, 2023

Every company uses energy and resources; every company affects, and is affected by, the environment. Every company operates within a broader, diverse society. Every company requires governance to function, operate and exist. Environmental, social and governance (ESG) imperatives impact every aspect of clinical trial operations. ESG is a collective term that measures a business’s impact on the environment, society at large and how robust and transparent its governance is in terms of company leadership, executive pay, audits, internal controls and shareholder rights.

The world is moving towards a greener economy — meaning that investors, financial institutions and the general public all want to see evidence of ESG activities associated with the money they make available to organizations.

A business’s reputation is increasingly defined not just by how effective its products are, its customer service, but also by how invested it is around ESG. This has knock-on secondary effects such as being a deciding factor for customers and talent.

These efforts are now a decision-making factor for companies on who they want to work with. Companies with strong ESG credentials and ambitions want to and indeed must work with other companies on a similar path if they are to achieve their targets. While currently voluntary, ESG will likely soon become a regulatory requirement. Investing in ESG activities now is crucial in preparing for the future and reducing the exposure to risk. It makes good business sense to reduce waste, which in turn lowers costs and reduces the bottom line.

Join this webinar to learn how ESG will have a profound impact on how clinical operations work is performed. By understanding an organization’s position and needs, Clinical Operations Leaders have an opportunity to take an industry leading position in ESG.

Speakers

Carly Santer, Bayer UKI

Carly Santer, Impact Officer, Bayer UKI

Carly is Bayer’s first Impact Officer, a role which she created to ensure that the UK and Ireland organization interprets Bayer’s global sustainability strategy into positive impact, while coordinating the business’ response to the related local market pressure and customer expectations. This is to ensure that sustainability-related risks are mitigated and potential opportunities are recognized. She is working this year on further embedding sustainability into business decision making to increase long-term business resilience for Bayer UK and Ireland using the framework of the Well-being of Future Generations (Wales) Act 2015.

Message Presenter
James Man, Syneos Health Consulting

James Man, Managing Director, Syneos Health Consulting

Throughout his career in the life sciences industry, James Man has been guided by a passion for solving problems in healthcare. He has had years of expertise gained from successful project delivery and transformation program outcomes at companies ranging from Johnson and Johnson to Kinapse to Syneos Health, pairing a willingness to try new approaches and co-creating with partners

Message Presenter
James Taylor, Syneos Health Global Client Solutions

James Taylor, Vice President, Global Client Solutions Executive, Syneos Health Global Client Solutions

James Taylor is a clinical trial executive with extensive experience planning, contracting and executing global clinical trials including expertise in clinical portfolio and project management, CRO oversight, quality and compliance. He has significant experience in leading organizations, such as Pfizer and Sanofi-Aventis, through abrupt periods of change, building and mentoring effective leadership teams.

Message Presenter
Jennifer Anderson, Syneos Health Environmental, Social & Governance

Jennifer Anderson, Associate Director, Syneos Health Environmental, Social & Governance

Jennifer Anderson is a hardworking and ambitious individual who is currently working as an Associate Director in Environmental, Social and Governance at Syneos Health, based in London. She has been driven by an interest in sustainability, healthcare, business and global development. Throughout her career, she has always had a passion for innovation and collaboration, particularly in the areas of sustainability, health, government and business.

Message Presenter

Who Should Attend?

  • Directors
  • Marketing Officers
  • Clinical Operations Managers
  • ESG Officers

What You Will Learn

Attendees will:

  • UNDERSTAND how and why life sciences companies are being affected by environmental, social and governance (ESG) imperatives today
  • EXAMINE how clinical operations leaders should plan for their organization’s ESG priorities
  • CREATE a plan to move the organization forward on ESG priorities

Xtalks Partner

Syneos Health® 

Syneos Health® (Nasdaq:SYNH) is a leading integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.

Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. We support a diverse, equitable and inclusive culture.

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account